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I. INTRODUCTION
In recent years, the rapid expansion of knowledge in the field of
molecular genetics resulting from the use of recombinant DNA
(rDNA) techniques has been unprecedented. The expanded knowl-
edge scientists have acquired through rDNA techniques has pre-
cipitated conspicuous breakthroughs in biomedical research involv-
ing the manipulation of human genetic material to diagnose and
treat human disorders.' Application of this research may soon af-
fect all aspects of our lives.2 However, this newly-acquired ability
* Associate, Hunton and Williams; B.A., 1967, University of Texas; Ph.D., 1971, Univer-
sity of Minnesota; J.D., 1984, University of Texas.
** Visiting Scholar, Science, Technology & Society Program and The Center for Policy
Alternatives, Massachusetts Institute of Technology; B.A., 1971, University of California,
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1. Currently, four proposals have been or will be submitted to the National Institutes of
Health for permission to attempt to insert rDNA into humans. See Chase, Scientists Hope
to Put New Genes in Victims of 2 Genetic Diseases, Wall St. J., Jan. 26, 1984, at _ col.
- Investigators are attempting to place human growth genes in livestock. The National
Institute of Health was asked to restrict this research, but has refused to do so. 49 Fed. Reg.
37,016 (1984). See also Gordon & Ruddle, Integration and Stable Germ Line Transmission
of Genes Injected into Mouse Pronuclei, 214 Sci. 1244 (1981); Grouse, Restriction Enzymes,
Interferon, and the Therapy for Advanced Cancer, 247 J. A.MA 1742 (1982); Marx, Three
Mice "Cloned" in Switzerland, 211 Sci. 375 (1981); Spradling & Rubin, Transposition of
Cloned P Elements into Drosophila Germ Line Chromosomes, 218 Sci. 341 (1982);
Scbmeck, Injection of a Gene Cures Flaw in Cell, N.Y. Times, Oct. 10, 1979, at A14, col. 1.
See generally Motulsky, Impact of Genetic Manipulation on Society and Medicine, 219
Sci. 135 (1983).
2. See generally OFFICE OF TECHNOLOGY ASSESSMENT, U.S. CONGRESS, IPACT OF APPLIED
2 UNIVERSITY OF RICHMOND LAW REVIEW [Vol. 19:1
to manipulate human genes raises broad ethical and legal ques-
tions. The issues raised by rDNA research are dissimilar to earlier
questions regarding the use of genetically-engineered microorga-
nisms in the laboratory and current questions related to the regu-
lation of biotechnology.3 Despite this dissimilarity, the rapidity
with which biomedical developments have been achieved makes
the resolution of these ethical and legal questions regarding rDNA
techniques all the more urgent.4
A new technique developed through rDNA research permits a
direct examination of the chemical organization of an individual's
genetic material. 5 The most immediate application of this tech-
nique is its use in safe, accurate, and reliable genetic screening.
Recently, genetic screening has been carried out for a few heredi-
tary diseases, raising a variety of ethical and legal issues.6 These
concerns are likely to be extended and intensified since rDNA
technology potentially permits screening for any hereditary factor.
GENETICS ON MICROORGANISMS, PLANTS, AND ANIMALS (1981); Teso, The Promise of Biotech-
nology ... and Some Constraints, OECD OBSERVER, Sept. 1982, at 4. For additional com-
ment, see Cooke, Engineering a New Agriculture, 85 TECH. REV. 22 (1982); Fox, Genetic
Engineering Industry Emerges, CHEM. & ENG'G NEWS, Mar. 17, 1980, at 15; Marx, Agricul-
tural Applications of Genetic Engineering, 216 Sci. 1306 (1982); Swaminathan, Biotechnol-
ogy Research and Third World Agriculture, 218 Sci. 967 (1982); Yanchinski, Chemical Gi-
ants Turn to Biotechnology, NEW SCIENTIST, Nov. 6, 1980, at 349.
3. See Foundation on Economic Trends v. Heckler, 14 ENvTL. L. REP. (EN vL. L. INST.)
20,467 (May 16, 1984) (National Institute of Health must prepare an environmental impact
statement under the National Environmental Policy Act before changing its rDNA guide-
lines to permit the release of genetically-engineered microorganisms into the environment);
STAFF OF HOUSE SUBCOMM. ON INVESTIGATIONS AND OVERSIGHT, COMM. ON SCIENCE AND TECH-
NOLOGY, 98TH CONG., 2D SESS., THE ENVIRONMENTAL IMPLICATIONS OF GENETIC ENGINEERING
(Comm. Print 1984). See generally Sun, Biggest Challenge Since the Double Helix, 212 SCL
28 (1981).
4. Although much remains to be learned in this field, knowledge is being acquired rapidly.
in most areas of research, 'new' means something that has been found within the past
five years but in molecular biology it often means something found within the past
few months-or even last week. Time and time again in the past ten years, the speed
with which events have unfolded has taken well-informed observers by surprise.
PRESIDENT'S COMMISSION FOR THE STUDY OF ETHICAL PROBLEMS IN MEDICINE AND BIOMEDICAL
AND BEHAVIORAL RESEARCH, SPLICING LIFE: A REPORT ON THE SOCIAL AND ETHICAL ISSUES OF
GENETIC ENGINEERING WITH HUMAN BEINGS 13 (1982) [hereinafter cited as PRESIDENT'S COM-
MISSION, SPLICING].
5. For a full description of the technique, see infra notes 25-32 and accompanying text.
FDA approval has been sought for this diagnostic test. Letter from Edward N. Brandt, As-
sistant Secretary of Health, Department of Health and Human Services, to Congressman
John D. Dingell (Sept. 13, 1984).
6. See PRESIDENT'S COMMISSION FOR THE STUDY OF ETHICAL PROBLEMS IN MEDICINE AND
BIOMEDICAL AND BEHAVIORAL RESEARCH, SCREENING AND COUNSELING FOR GENETIC CONDI-
TIONS 17-22, 93-94 (1983) [hereinafter cited as PRESIDENT'S COMMISSION, SCREENING].
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This paper will explore some of the ethical and legal implications
of the biomedical application of rDNA research and the adequacy
of existing regulatory mechanisms to deal with them. The paper
demonstrates that the existing mechanisms for regulating these di-
agnostic procedures do not adequately address the problems they
present.
II. NEW GENETIC DIAGNOSTIC TECHNIQUES DEVELOPED FROM
rDNA RESEARCH
A. Historical Background7
Before 1978, physicans employed two laboratory techniques for
identifying genetic disorders. Under the first technique, the physi-
can could examine chromosomes8 prepared from a patient's white
blood cells to diagnose genetic problems associated with the pres-
ence of an additional chromosome9 and to identify chromosomes
damaged by environmental toxins. 10 The second technique em-
ployed biochemical assays to detect deficiencies in the products
produced by particular genes.11 This technique has been used to
identify a limited number of genetic disorders.12
7. For a description of genetic diagnostic procedures and genetic disorders, see Note, Fa-
ther and Mother Know Best: Defining the Liability of Physicians for Inadequate Genetic
Counseling, 87 YALE L.J. 1488, 1490-94 (1978). See also Hsia, The Law and Operation of
Genetic Screening Programs, in GENETms AND THE LAW 1197 (A. Milunsky & G. Annas ed.
1980); Milunsky, Prenatal Diagnosis of Genetic Disorders, 295 NEW ENG. J. MED. 377
(1976).
8. The basic biochemical unit of genetic material is DNA (deoxyribonucleic acid), a
double-stranded helical molecule composed of nucleotides (bases). The bases along one
strand of the helix are paired with their complementary nucleotides on the second strand.
The pair of complementary nucleotides is referred to as a base pair. A group of bases along
the strand that code for a particular functional unit, often a protein, is called a gene. The
sequence of bases along the strand determines the structure of the protein. When one or
more nucleotides in the sequence are substituted or deleted, or when an additional base or
bases are added, the structure of the protein produced is likely to be altered. These are
referred to as a gene substitution, a gene deletion, and a gene insertion, respectively. Any
such change can be manifested as a genetic disorder. Groups of genes are organized into
structures called chromosomes. The total complement of chromosomes within the nucleus is
called the genome. In humans, the genome consists of twenty-three pairs of chromosomes
with one chromosome in each pair being of "maternal" origin and one of paternal origin. See
generally J. WATSON, THE MOLECULAR BIOLOGY OF THE GENE (3d ed. 1977).
9. See Milunsky, supra note 7, at 378.
10. For a brief description of the significance of this diagnostic approach, see Kolta, Chro-
mosome Damage: What It Is, What It Means, 208 Sci. 1240 (1980).
11. See Milunsky, supra note 7, at 379.
12. See Golbus, The Antenatal Detection of Genetic Disorders, 48 OBSTrET. AND GYrEcoL.
497 (1976).
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These techniques have been employed to predict the likelihood
of a couple giving birth to a child with a genetic disorder. Before
1960, genetic disorders had to be identified in the parents or earlier
offspring, and a statistical projection made of the likelihood that
the trait would appear in later children. In the early 1960's, the
development of amniocentesis, a technique for obtaining amniotic
fluid from the womb of a mother, made possible the chromosomal
and biochemical analysis of fetal cells and amniotic fluid.13 Thus,
certain disorders could be detected in utero, eliminating some of
the uncertainty in prenatal diagnosis. However, these prenatal di-
agnostic procedures were not infallible and amniocentesis itself
still presents some minimal risks to the mother and infant.1 4
In the mid-1970's, the development of fetoscopy, a technique for
obtaining blood directly from the fetus, permitted physicians to di-
agnose certain hemoglobin disorders directly in the fetus." In ad-
dition, genetic diagnostic techniques were employed postnatally to
identify genetic traits. Postnatal chromosomal analysis has been
used to identify candidates for compulsory sterilization'6 and to
predict the likelihood of violent tendencies in certain individuals."7
13. For a general description of the amniocentesis technique, see W. FUHRMAN & F. VO-
GEL, GENETIC COUNSELING 91-92 (2d ed. 1976).
14. The incidence of spontaneous abortions induced by amniocentesis is about 0.5% (one
out of 200 cases). The NICHD National Registry for Amniocentesis Study Group, Mid-
trimester Amniocentesis for Prenatal Diagnosis, 236 J. A.MA 1471 (1976). This risk ap-
pears low, however, in a woman 35 years of age the risk of bearing an infant with Down's
Syndrome is only one out of 365.
15. Kan, Golbus, Trecartin & Filly, Prenatal Diagnosis of B-Thalassemia and Sickle Cell
Anemia: Experience with 24 Cases, 1977 LANCET 269. Hemoglobin is a molecule found in
red blood cells which carries oxygen in the blood. Genetic disorders of hemoglobin occur in
two types. One type involves a single base pair substitution in the globin gene. This disorder
is referred to as a hemoglobinopathy, the most common example of which is sickle cell ane-
mia. Several variants of this disorder occur. The trait is inherited in simple Mendelian fash-
ion; hence the disease manifests itself in the homozygous condition, while the heterozygote
is merely a carrier for the trait. (Mendelian inheritance simply states that some characteris-
tics are derived from one parent while other characteristics are derived from the other par-
ent. STEDMAN'S MEDICAL DICTIONARY 710 (5th unabr. lawyer's ed. 1982)). The second type of
disorder results from deletions in the globin gene that cause a decrease in the amount of the
globin molecule produced by the red blood cells. The a- and P-thalessemias are the most
common examples of this disorder. See J. WATSON, supra note 8. See also Bank, Mears &
Ramirez, Disorders of Human Hemoglobin, 207 Sci. 486 (1980). Before 1976, these disorders
could not be diagnosed directly. Since 1976, the development of a new technique, fetoscopy,
allows the hemoglobin to be examined prenatally from samples of fetal blood. However,
fetoscopy has a five percent abortion rate. See Orkin, Little, Kazazian & Boehm, Improved
Detection of the Sickle Mutation by DNA Analysis, 307 NEW ENG. J. MED. 32, 33 (1982).
16. See Wexler, "Will the Circle Be UnBroken?," Sterilizing the Genetically Impaired,
in GENETICS AND THE LAW II 313 (1980).
17. See Jacobs, Aggressive Behavior, Mental Subnormality and the XYY Male, 208 NA-
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Specific genetically-linked biochemical markers have been identi-
fied which are linked to an increased susceptibility to cancer,"8 de-
pression,19 and the toxic effects of industrial chemicals. 0
In 1978, investigators applied techniques developed in rDNA re-
search to detect a hemoglobin disorder from the DNA obtained
from cells in the amniotic fluid.21 The significance of this experi-
ment was that, for the first time, a genetic disorder was diagnosed
directly from the DNA, rather than indirectly from an analysis of
the chromosomes or gene products. This technique is more sensi-
tive than other methods of genetic diagnosis because it reveals
small differences in the DNA of a gene itself rather than changes
in the number or the appearance of chromosomes, or in the
amount or structure of a gene product.22 This new diagnostic ap-
TURE 1351 (1965) (seminal article on the topic). Evidence suggested that the presence of an
additional Y sex chromosome in males was associated with a propensity for violence and
antisocial behavior. This work is extremely controversial. For a detailed discussion of the
research and its implications, see HASTINGS CENTER REPORT, SPECIAL SUPPLEMENT THE XYY
CoNTRovERsY, RESEARCHING VIOLENCE AND GENETICS (August 1980).
18. For example, relatives of patients with the rare genetic disorder, ataxia-telangiectasia,
are five times more likely to die of cancer before age 45 than members of the public at large.
For a provocative discussion of this observation and the ethical dilemmas posed by this
knowledge see Kolata, Testing for Cancer Risk, 207 SCi. 967 (1980). See also Maugh, Center
Tests Look for a Passing Grade, 211 Sci. 909 (1981) (reviewing the status in the regulatory
process of eight tests for cancer based on specific gene products).
19. See Weitkamp, Stancer, Persad, Flood & Gultormsen, Depressive Disorders and
HLA: A Gene on Chromosome 6 That Can Affect Behavior, 305 NEw ENG. J. MED. 1301
(1981) (demonstration that familial depression is linked to an HLA gene on chromosome
six). See generally Maugh, Is There a Gene for Depression?, 214 SCL 1330 (1981).
20. Currently at least two tests are available for detecting a potential hypersensitivity to
toxic substances. One test is based upon a genetically-linked deficiency in glucose-6-
phosphate dehydrogenase, a deficiency which is more prevalent in black males and Mediter-
ranean Jews. This deficiency can lead to anemias upon exposure to chemicals such as
napthalene. The other test is based upon detecting a genetically-linked deficiency in a -1-
antitrypsin. This deficiency predisposes an individual to lung disorders and emphysema
with exposure to lung irritants. The homozygous form of the trait is linked to emphysema.
For a general discussion of the tests, see Holden, Looking at Genes in the Workplace, 217
Sci. 336 (1982). For a discussion of the legal and regulatory implications of these tests, see
Genetic Screening of Workers: Hearings Before the Subcomm. on Investigations and Over-
sight of the House Comm. on Science and Technology, 97th Cong., 2d Sess. 45, 92-107
(1984) (testimony of Professor Mark Rothstein, College of Law, West Virginia University)
[hereinafter cited as Hearings, Genetic Screening]; Peppleson, Genes and Jobs, 68 A.BA J.
1061 (1982); McGarity & Schroeder, Risk-Oriented Employment Screening, 59 TEx. L. REv.
999 (1981). For a discussion of the ethical implications, see Lapp6, Ethical Issues in Testing
for Differential Sensitivity to Occupational Hazards, 25 J. OccuP. MED. 797 (1983).
21. Orkin, Alter & Altay, Application of Endonuclease Mapping to the Analysis and
Prenatal Diagnosis of Thalassemias Caused by Globin-gene Deletion, 299 NEW ENG. J.
MED. 166 (1978); Kan & Dozy, Antenantal Diagnosis of Sickle Cell Anemia by DNA Analy-
sis of Amniotic-Fluid Cells, 1978 LANCET 910.
22. This point is essential for appreciating the sensitivity of the technique. The Restric-
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proach is readily adaptable for identifying numerous other genetic
problems, including many for which no other diagnostic procedure
exists.23
B. Genetic Diagnosis Using Restriction Enzyme Analysis of
DNA
1. A Simplified Description of the READ Technique
Restriction Enzyme Analysis of DNA (READ) 4 uses fetal DNA
obtained from cells in the amniotic fluid. A restriction enzyme2
breaks the DNA into fragments which are separated according to
size. Probes of single-stranded radioactive DNA26 are used to iden-
tion Enzyme Analysis of DNA (READ) technique can detect a single nucleotide difference
in an individual's DNA. The other approaches look at second order and third order products
that merely reflect the changes in the DNA.
23. See Kronenberg, Looking at Genes, 307 NEw ENG. J. MED. 50, 51 (1982); Motulsky,
Impact of Genetic Manipulation on Society and Medicine, 210 Sci. 135, 137 (1983); PREsI-
DENT'S COMMISSION, SCREENING, supra note 6, at 40-41. The availability of other tests to
diagnose genetic disorders depends upon the existence of a test that is sufficiently sensitive
to detect small changes in the amount and/or the chemical structure of a particular protein
(usually an enzyme). Since these proteins are only present in certain cell types in the body,
another limitation is the ability to obtain a sufficient quantity of the specific cells needed for
analysis. The hemoglobin disorders illustrate these limitations. See supra note 15. Before
the advent of the new diagnostic technique, it was necessary to obtain hemoglobin from the
fetus to detect alterations in the globin molecule. This hemoglobin is only present in suffi-
cient amounts to analyze its protein sequence in blood cells. Thus in order to detect these
disorders prenatally a technique had to be developed to remove blood from the fetus in
utero. This procedure was not developed until the mid-1970's and even now carries a signifi-
cant risk to both the mother and fetus. Even assuming that a sufficient quantity of the
material from the appropriate cells can be obtained, many tests are not sensitive enough to
detect the small changes in the protein that may significantly alter cellular functions. The
new diagnostic technique avoids these problems since it analyzes the DNA directly. Only
small amounts of DNA are required; moreover, the DNA can be obtained from any cell since
identical DNA is present in all tissues of the body in equal amounts. If aditional DNA is
required, the cells can be cultured. Since DNA replicates before each cell division, the
amount of DNA doubles with each division in culture. Thus the new approach does not have
the limitations in terms of requiring a specific cell type for analysis and large amounts of
material. This approach is potentially available for detecting alterations of any single gene
defect.
24. For a general, but more specific description of the READ technique, see Kronenberg,
supra note 23.
25. A restriction enzyme (or restriction endonuclease) is an enzyme that breaks down
DNA at specific sites. Different restriction enzymes break (or recognize) the DNA at differ-
ent sites. These cites are determined by the sequence of nucleotides in the DNA. The en-
zyme is named for the bacteria from which it is isolated. See Chang, Golbus & Kan, Antena-
tal Diagnosis of Sickle Cell Anemia by Sensitive DNA Assay, 1982 LANCET 1463.
26. A probe is a single stranded DNA molecule containing a part or all of a gene which is
sought to be identified. The probe is constructed in the laboratory by synthesizing the se-
quence of nucleotides known to constitute or comprise part of the gene being studied. The
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tify the fragments of DNA that comprise the gene of interest, for
example, the globin gene. If a part of the globin gene is absent,2"
or if a base-pair substitution2" is present in the region of the gene
recognized by the restriction enzyme, s° the size of the DNA frag-
ments comprising the globin gene will be different from that ob-
served when DNA from a normal patient is analyzed. Thus, READ
permits the detection of discrete changes in genetic material. This
diagnostic technique has been used successfully to detect a- and fi-
thalassemias31 as well as one form of sickle cell 4nemia 2 which
probe is made radioactive by the substitution of phosphorus 32. Less expensive, fluorescent
probes have recently been developed. See Chang & Kan, A Sensitive New Prenatal Test for
Sickle Cell Anemia, 307 NEw ENG. J. MED. 30, 31 (1982). In the READ technique, the DNA
obtained from fetal cells is treated to separate the two strands of the DNA helix after the
DNA is segregated by the size of the fragment. The radioactive probe binds the fragment of
DNA containing the gene or part of the gene in the probe since the single strand of the
probe DNA will bind to the complementary single strand of the fragment DNA.
27. See supra notes 8, 15 & 23.
28. Id.
29. Id.
30. The utility of the READ technique depends upon having a restriction enzyme that
recognizes a site in a gene in which a change has taken place. The number of different
restriction enzymes available (approximately 150) does not make this an insurmountable
obstacle. See Kronenberg, supra note 23, at 51. Nonetheless, the technique can be modified
to circumvent this limitation by looking at non-coding regions of the genes or regions of the
DNA adjacent to the genes recognized by the restriction enzymes which have changes in
them. The sequences of DNA within genes and adjacent to genes which do not code for a
protein have a sequence which is specific for that location on the DNA molecule. Variations
in the DNA sequence occur in specific genetic populations or associated with specific
changes within the gene. Because these non-coding regions normally vary slightly in their
base sequence throughout the general population, they are referred to as polymorphic re-
gions of the DNA. These polymorphic regions are common in the genome and are inherited
in a simple Mendelian fashion. (See supra note 15). Familial studies have revealed the
linkage of specific genes and genetic disorders to specific polymorphisms. See Levin, Jump-
ing Genes Help Trace Inherited Diseases, 211 ScL 690 (1981). It is estimated that if as few
as 165 polymorphic regions, evenly distributed through the genome, can be identified, scien-
tists will be able to have a complete linkage map for all genetic disorders. See Botstein,
White, Skolnick & Davis, Construction of a Genetic Linkage Map in Man Using Restric-
tion Fragment Length Polymorphisms, 32 AM. J. Hum GEN. 314 (1980). There is some argu-
ment about the strength of the linkage of a genetic disorder to a specific polymorphism.
Compare Kan & Dozy, supra note 21, at 910 (95% frequency of linkage of sickle cell gene to
Hpa I restriction enzyme polymorphism) with Bank, Mears & Ramirez, supra note 15, at
491-92 (60% frequency).
31. Thalassemia is a group of inherited disorders of hemoglobin metabolism in which
there is a decrease in the net synthesis of a particular globin chain without a change in the
structure of that chain. Alpha-thalassemia is the result of depressed synthesis of a-globin
chains due to the presence of an abnormal gene. Likewise, f6-thalassemia is the result of
depressed synthesis of fl-globin chains. STEDMAN'S MEDIcAL DICTIoNARY 1435 (5th unabr.
lawyer's ed. 1982).
32. See Chang, Golbus & Kan, supra note 25 (sickle cell anemia); Chang & Kan, supra
note 26 (sickle cell anemia); Little, Annison, Darling, Williamson, Camba & Modell, Model
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previously could be detected only by using samples of fetal blood.3
2. Potential Applications of the Technique
The READ technique can be easily adapted to identify altera-
tions in genes other than the globin gene.34 However, two factors
may limit the application of the technique to other genetic disor-
ders. The first relates to how rapidly the probes used to identify
fragments containing specific genes will become available. This fac-
tor represents only a minor obstacle to the expansion of the tech-
nique.3 5 The second factor is the availability of altered sites within
the gene which are close enough to the site recognized by a restric-
tion enzyme to permit detection.3 6 While this problem is formida-
ble, it has already been partially circumvented through the identi-
fication of polymorphic regions37 specifically linked to the gene
which has been recognized by a restriction enzyme.3 8 It has been
suggested that one need identify only 165 such polymorphic ge-
netic markers, that are equally distributed over the genome,3 9 to
detect any disease-producing gene.40
Parallel developments in other areas of biomedical research
should facilitate the development of READ applications. Cur-
rently, the technique requires the use of DNA from fetal cells ob-
tained by amniocentesis. In an unrelated area of research, a fluo-
rescence-activated cell sorter 41 has been developed which permits
the separation of maternal blood cells from fetal blood cells that
for Antenatal Diagnosis of B-Thalassemia and Other Monogenic Disorders by Molecular
Analysis of Linked DNA Polymorphisms, 285 NATURE 144 (1980) (6-thalassemia); Orkin,
Alter & Altay, supra note 21 (a-thalassemia); Orkin, Little, Kazazian & Boehm, supra note
15 (sickle cell anemia).
33. See Orkin, Little, Kazazian & Boehm, supra note 15.
34. See supra note 23.
35. See Levin, supra note 30, at 691. The number of genes whose sequence (or partial
sequence) is known has increased enormously in the past three years. The National Institute
of General Medical Sciences has established a computer library to store the sequences and
to make them available to all investigators. The ability to synthesize genes has been simpli-
fied to an automated technique. See Alvarado-Urbina, Sathe, Liv, Gillen, Duck, Bender &
Ogilvie, Automated Synthesis of Gene Fragments, 214 Sci. 270 (1981).
36. See supra note 25.
37. See supra note 30.
38. Id.
39. Id. See supra note 8.
40. See Botstein, White, Skolnick & Davis, supra note 30, at 315.
41. See generally Herzenberg, Sweet & Herzenberg, Fluorescence-Activated Cell Sorting:
A New Tool for Isolating Functional Cell Types, 234 SCL AM. 108 (Mar. 1976).
[Vol. 19:1
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have crossed the placenta.42 The cell sorter technique requires only
twenty milliliters of maternal blood to isolate the fetal cells. By
culturing these fetal cells,43 sufficient fetal DNA can be made avail-
able for analysis." Hence, it may soon be possible to use maternal
blood for prenatal diagnosis with the READ technique, thus sub-
jecting the mother and fetus to only a negligible risk.
The potential applications of READ are not limited to prenatal
diagnosis. The technique also may be used to detect genetic disor-
ders in adults; to screen for disorders such as Huntington's Dis-
ease, which do not manifest themselves until later in life;45 and to
detect genetic susceptibility to cancer, toxins, and other diseases.46
III. ETHICAL AND LEGAL IMPLICATIONS OF READ
READ dramatically extends the ability to diagnose genetic dis-
orders. This potential carries with it attendant ethical and legal
implications. The remainder of this paper attempts to identify
42. See Herzenberg, Biachi, Conn & Iverson, Detection and Isolation of Fetal Cells from
Maternal Blood Using the Fluorescence-Activated Cell Sorter (FACS), 1 PRENATAL DIAG-
NOSIS 61, 62 (1981). Currently, the technique is used to separate, identify, and collect cells of
male infants from maternal blood.
43. Id. at 72.
44. Id. at 73.
45. Motulsky, supra note 23, at 137. The average age of onset of Huntington's disease
(HD) is 41 years. HD is a progressive, debilitating disease that manifests itself in motor
dysfunction and often in mental and psychological disorders. The duration of the disease
from first symptoms to death averages 10 to 20 years. Treatment may ameliorate the symp-
toms for some patients for varying periods, but there is no cure. In the U.S., approximately
one in 10,000-15,000 suffer from the disease, but the gene frequency, and thus those who
will eventually have HD, is one in 4,000-10,000. Thus, in this country, about 10,000-25,000
have HD and an additional 20,000-50,000 are at 50 percent risk. It is a hereditary disease
that is independent of gender, and the presence of the gene will invariably eventually result
in the disease. Those who carry the gene and who will eventually have the disease cannot be
distinguished from those who do not. In this context, the status of the carrier, and thus the
meaning of the term, differs from that of carriers of recessive hereditary disease genes who
do not have the disease but may have offspring who do. Those who have the gene for HD
will get the disease; anyone with a parent who has HD is at 50 percent risk of having the
gene, and conversely, anyone with H) has a 50 percent chance of passing it on to each child.
Although the gene for Huntington's disease has not been identified, a polymorphic marker,
genetically linked to Huntington's disease, has been identified. See Gusella, A Polymorphic
DNA Marker Genetically Linked to Huntington's Disease, 306 NATURE 234 (1983). Identifi-
cation of the gene itself is only a matter of time.
46. See Shafritz, Shouval, Sherman, Hadziyannis & Kew, Intergration of Hepatitis B vi-
rus DNA into the Genome of Liver Cells in Chronic Liver Disease and Hepatocellular Car-
cinoma: Studies in Percutaneous Liver Biopsies and Post-Mortem Tissue Specimens, 305
NEW ENG. J. MED. 1067 (1981) (detection of viral hepatitis and hepatoma). See also supra
notes 18 & 20.
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some of these ethical and legal implications and to determine
whether regulatory strategies exist to address them.
A. READ and Prenatal Diagnosis
One of the central ethical conflicts of any prenatal diagnostic
technique is the extent to which information from that technique
should influence the decision to bear a child. The legal aspect of
this ethical conflict concerns the role of the state in effecting that
decision, regardless of its basis. The availability of the READ tech-
nique complicates resolution of this conflict. Because the technique
is sensitive, rapid, and reliable, it can provide more information,
both significant and trivial, which may have an impact on the deci-
sion to bear a child. In addition, existing case law in the area of
wrongful birth may impose a duty on physicians to provide this
information. At the same time, because test results can be availa-
ble within the first trimester, the state may be precluded from af-
fecting the decision-making process. 47
1. The Role of Information in the Decision to Bear a Child
Use of READ for prenatal diagnosis extends the ability to diag-
nose genetic disorders that may seriously impair postnatal viability
of the fetus or that may endanger maternal health during preg-
nancy and childbirth. However, the technique can also be used to
detect disorders that do not present a significant threat to either
mother or newborn, or to identify genetic traits of unknown or
neutral eugenic value. Thus, READ may increase the likelihood
that abortion will be utilized to enforce genetic preferences rather
than as a therapeutic procedure.
READ offers the only safe technique for diagnosing two forms of
thalassemia.4 Tests using the technique should soon be available
for detecting growth hormone deficiency, phenylketonuria and
Duchenne's muscular dystrophy,49 and possibly for Lesch-Nyhan
47. See Planned Parenthood v. Danforth, 428 U.S. 52 (1976) (overturning a state law ban-
ning the use of saline amniocentesis as a techniquefor abortions. The Court held that the
statute was related to the health of the fetus, not the mother.).
48. See supra note 31 & 32.
49. Human Genetic Engineering: Hearings Before the Subcomm. on Investigations and
Oversight of the House Comm. on Science and Technology, 97th Cong., 2d Sess. 223, 242,
292 (1982) [hereinafter cited as Hearings, Engineering]. For a description of the disorders,
see Annas & Coyne, "Fitness" for Birth and Reproduction: Legal Implications of Genetic
Screening, 9 FAM. L. Q. 463 nn.9-10 (1975).
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disease.50 Each of these disorders either seriously threatens the
mother or causes a painful or debilitating condition in the off-
spring that severely shortens its life-expectancy. No effective treat-
ment exists for these disorders and, because of their serious and
irremediable nature, it is reasonable to assume that the introduc-
tion of heretofore unavailable prenatal tests for these and similar
disorders may increase the number of abortions of fetuses with
such complications. However, concerns generated by this increase
in the number of abortions must be balanced against the potential
economic, social, and personal burdens that will be avoided if more
fetuses suffering from these conditions are aborted."
An additional factor should be considered. Procedures currently
available can, at best, determine that the chance a fetus will be
born with one of these disorders is one out of three.2 Any decision
to abort the fetus based upon that probability will inevitably result
in the loss of two viable, unimpaired fetuses for every affected fe-
tus. READ, however, can distinguish between those fetuses only
carrying the trait and those fetuses that actually have the disor-
der,53 thereby avoiding the abortion of two normal fetuses. But
even if READ is utilized, the decision to give birth to a carrier of a
deleterious genetic trait could increase the genetic load of that
trait in the general population. 4
READ offers the potential for identifying the presence or ab-
sence of any trait controlled by a single gene; thus, its potential
50. See Hearings, Engineering, supra note 49, at 223.
51. The cost of caring for an infant with Tay-Sachs disease is $20,000-40,000 per year.
The total cost to society of caring for children with Down's Syndrome is 1.7 billion dollars
per year. See H.R. REP. No. 498, 94th Cong., 2d Sess., reprinted in 1976 U.S. CODE CONG. &
AD. NEws 709, 727. See also Thompson & Milunsky, Policy Analysis for Prenatal Genetic
Diagnosis, 27 Pun. POL'Y 25 (1979). See generally PRES DENT'S COMMISSION, SCREENING,
supra note 6, at 47-53 (a discussion of the policy implications of compulsory genetic screen-
ing; however, the discussion highlights many of the implications of genetic disease).
52. The other two positive results will only be carriers of the trait. See PRESIDENT'S COM-
MISSION, SCRENING, supra note 6, at 111-15. Genetic counselors usually consider a risk of one
out of ten to be sufficiently high to recommend not having a child. See Carter, Roberts,
Evans & Buck, Genetic Clinic: A Follow-Up, 1971 LANCET 281. See also Note, The Consti-
tutionality of Mandatory Genetic Screening Statutes, 31 CASE: W. RES. 897 n.2 (1981).
53. See supra notes 32-40 and accompanying text.
54. The genetic load is a measure of the frequency of a gene in the population. By in-
creasing the number of carriers in the population the frequency of the deleterious gene in-
creases and, also, the probability of a homozygous offspring with the disorder. Friedman
suggests that, if the carriers for sickle cell anemia and cystic fibrosis could be identified with
amniocentesis, fourteen million abortions over a span of forty years could eliminate the
genes from the population. Friedman, Legal Implications of Amniocentesis, 123 U. PA. L.
REV. 92, 107-08 (1974).
1984]
UNIVERSITY OF RICHMOND LAW REVIEW
application extends beyond detecting genetic disorders which are
debilitating from birth. For example, Huntington's disease is a se-
vere, disabling genetic disease with a late onset 55 for which READ
is likely to offer a safe test for prenatal detection.5" The informa-
tion obtained may be used to decide whether to bear a child with
this genetic defect, just as in the case of the prenatal diagnosis of
any serious genetic disorder. However, the relative significance of
this information in making a meaningful decision in this instance
differs from a similar decision regarding serious disorders that be-
gin at or shortly after birth, because the economic, social, and per-
sonal consequences of the disease are manifestly different.
The ethical dilemmas posed by the READ technique become in-
creasingly complex when one considers the potential of the tech-
nique to identify traits whose possible deleterious effects merely
increase an offspring's susceptibility to a disease,57 rather than ac-
tually causing the disease. READ should soon by available to test
for the presence of a genetic defect which affects the production of
an enzyme, a-1 antitrypsin s.5  Persons with this defect are more
susceptible to pulmonary disorders such as emphysema,59 although
the degree of increased risk is a matter of great controversy.60 The
ethical problems posed by a decision to abort a fetus based upon
the unquantified possibility of increased risk of disease are defi-
nitely more complex than those problems posed by a similar deci-
sion to abort based upon the certainty of delivering a non-viable
genetically defective child. Furthermore, a decision to abort based
upon neutral genetic traits revealed by READ"' raises serious ethi-
55. See supra note 45.
56. See Gusella, supra note 45.
57. See supra note 20.
58. See Hearings, Engineering, supra note 49, at 292.
59. Genetic Screening and Handling of High Risk Groups in the Workplace: Hearings
Before the Subcomm. on Investigations and Oversight of the House Comm. on Science and
Technology, 97th Cong., 1st Sess. 151 (1981) (statement of Dr. Gilbert Omenn) [hereinafter
cited as Hearings, High Risk].
60. About one in 10,000 persons have a deficiency of this protein: and are predisposed to
develop emphysema and other pulmonary disorders. See supra note 20. Carriers may also
have a greater predisposition to lung disorders and sensitivity to airborne pollutants. Other
genetic deficiencies in genes that control enzymes such as glucose-6-phosphate
dehydrogenase and paroxnase may also predispose a worker to greater susceptibility to toxic
substances and pesticides. Similarly, the aryl-hydrocarbon hydroxylase genes may control
the breakdown of numerous carcinogens. The presence of particular genes, such as onco-
genes, may indicate a greater susceptibility to cancer. See Hearings, High Risk, supra note
59, at 145-51.
61. A neutral genetic trait would be a genetic trait that has neither deleterious nor adap-
tive consequences for the organism. Eye color would be an example of a multigene neutral
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cal concerns. A similar problem has already been confronted in re-
gard to the ability to identify the sex of a fetus through amni-
ocentesis.6 2 If the number of such possibilities increases through
the development of the READ technique, the dilemma created by
this problem may demand legal resolution.
2. The Role of Courts in Affecting Dissemination of Information
From READ
In recent years, courts have placed a duty upon physicians to
provide pregnant women with information about their potential for
bearing a genetically defective child so that the parents can make
an informed decision about whether to terminate the pregnancy.63
trait. A number of such single gene traits have recently been reported such as a single gene
that controls verbal ability. Hearings, Engineering, supra note 49, at 247.
62. See Fletcher, Ethics and Amniocentesis for Fetal Sex Identification, 301 NEW ENG. J.
MED. 550 (1979) (an argument that a woman's reproductive interests include the right to
elect to abort a fetus because of its gender). Cf. Powledge & Fletcher, Guidelines for the
Ethical Social and Legal Issues in Prenatal Diagnosis, 300 NEW ENG. J. MED. 168, 172
(1979). Some doctors, when confronted with information about the sex of a fetus obtained
from karyotypes of fetal chromosomes after amniocentesis, choose to withhold that informa-
tion rather than have the information form the basis for a decision to elect an abortion.
Hence, the physician assumes the burden of resolving the ethical dilemma. See, e.g., Powl-
edge, Letter to the Editor, 302 NEW ENG. J. MED. 524 (1980) (in response to Fletcher's
argument). However, the physician may be unable to make such decisions with the informa-
tion obtained from READ. In the first place, many disorders revealed with READ may not
be as trivial clinically as the gender of the fetus. Moreover, a growing minority of courts
place a duty upon a physician to provide parents with information upon which to base an
informed decision about whether to seek an abortion in instances where the infant may not
have a "meaningful" life. See infra notes 63-70 and accompanying text.
63. For a description of the wrongful birth cause of action, see Note, supra note 7. This
Note played an important role in shaping the court's approach to this cause of action in
Berman v. Allen, 80 N.J. 421, -, 404 A.2d 8, 14 (1979). In Berman the physician failed to
inform a 38-year-old mother of the availability of amniocentesis to diagnose Down's Syn-
drome. The Berman court allowed the parents of the subsequent mongoloid child to recover
damages for mental and emotional anguish because the mother had been tortiously deprived
of the option of making a meangful decision as to whether to abort the'fetus. Since Berman,
the New Jersey courts have expanded the cause of action. See Schroeder v. Perkel, 87 N.J.
53, 432 A.2d 834 (1981) (reversed and remanded lower appellate court's decision to grant a
summary judgment in favor of a physician. The plaintiff charged that the physician mis-
diagnosed cystic fibrosis in her first child early enough to afford her the opportunity to
decide whether to abort a second child.); Comras v. Lewin, 183 N.J. Super. 42, 443 A.2d 229
(1982) (reversed and remanded lower court dismissal of a suit charging a physician's negli-
gent failure to make a timely diagnosis of pregnancy to permit a woman with diabetes to
decide to have an abortion).
The courts in Virginia, California, and Washington have upheld a cause of action for
wrongful birth. See Turpin v. Sortini, 31 Cal. 3d 220, 643 P.2d 954, 182 Cal. Rptr. 337 (1982)
(failure to advise parents of possibility that fetus may be born congenitally deaf); Call v.
Kezian, 135 Cal. App. 3d 189, 185 Cal. Rptr. 103 (1982) (failure to diagnose and test for
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When a defective child is born, the physician's breach of this duty
gives rise to a cause of action for the tort of wrongful birth. In
developing this tort doctrine, the courts have neither defined the
parameters of the standard of care owed by the physician, nor rec-
ognized the implications of the rapidly expanding developments in
prenatal diagnosis and gene therapy. The continued expansion of
this doctrine, in light of recent developments such as the READ
technique, may have untold consequences for the practice of
medicine and for the privacy interests of patients.
Courts applying the wrongful birth doctrine purport to do noth-
ing more than extend the law of medical malpractice to prenatal
diagnosis. The cases decided under the doctrine divide into three
groups based upon the nature of the duty owed to the patient. In a
majority of the cases the physicians were held liable for the failure
to detect the genetic disorder in the fetus after undertaking to do
so. 4 In a small number of cases, the physicans were held liable for
failing to warn the patient of the risks and to advise her of the
availability of tests to determine whether the risk would come to
fruition.6 5 In a single recent case, the California Court of Appeals66
interpreted the tort of wrongful birth as requiring a physician to
actually test for the presence of a disorder and advise the parents
of the results of the test.6 7
In each of the three groups of cases, the court purported to hold
the physician to the standard and degree of care and skill expected
of the average practitioner in that specialty. Yet, in the second
Down's Syndrone in middle-aged pregnant mother); Curlender v. Bio-Science Laboratories,
106 Cal. App. 3d 811, 165 Cal. Rptr. 477 (1980) (court held for an infant plaintiff born with
Tay-Sachs Disease against physician and genetic test laboratory. The laboratory reported
the wrong results of an initial screening of the plaintiff's parents' blood for Tay-Sachs trait.
Apparently, in reliance upon the test, parents failed to elect further diagnostic tests using
amniocentesis.); Naccash v. Burger, 223 Va. 406, 290 S.E.2d 825 (1982) (failure to discover
Tay-Sachs Disease); Harbeson v. Parke-Davis, Inc., 98 Wash. 2d 460, 656 P.2d 483 (1983)
(failure to tell of material risks of dilantin treatment to pregnant mother).
64. See Turpin, 31 Cal. 3d 220, 643 P.2d 954, 182 Cal. Rptr. 337; Curlender, 106 Cal. App.
3d 811, 165 Cal. Rptr. 477; Schroeder, 87 N.J. 53, 432 A.2d 834; Comras, 183 N.J. Super.
A.D. 42, 443 A.2d 229; Naccash, 223 Va. 406, 290 S.E.2d 825.
65. See Berman, 80 N.J. 421, 404 A.2d 8; Harbeson, 98 Wash. 2d 460, 656 P.2d 483.
66. Call, 135 Cal. App. 3d 189, 185 Cal. Rptr. 103.
67. We hold here only that an attending physician is under a duty, when treating a mid-
dle-aged woman, to test for Down's Syndrome and to advise the parents of the results
of the test, leaving to the parents the decision as to seeking an abortion or permitting
the fetus to develop to the point of delivery.
Id. at 191, 185 Cal. Rptr. at 105.
68. In Washington, the standard of care used to measure physician negligence is not lim-
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category of cases, where physicians failed to inform their patients
of the availability of tests for birth defects, the standard appeared
to relate more to the materiality of the information to the patient
rather than to the standard of care in the relevant medical commu-
nity.6 9 The courts, however, have not defined materiality in any
terms that would allow one to predict the circumstances under
which a court might hold the likelihood of a particular disorder to
be material. In addition, the courts have not indicated whether the
existence of prenatal gene therapy or postnatal treatment or the
degree of physical impairment to the infant would be relevant to
the standard of care issue or merely to the damages issue.
Given the fact that the READ technique appears to be a highly
accurate diagnostic tool that can be coupled with safe, perhaps
even noninvasive procedures, it seems likely that its use will be-
come widespread and accepted by the medical community. Be-
cause it may soon be possible to use the technique to test for a
great variety of genetic characteristics, physicians may soon be
able to identify many genetic conditions that could be deemed ma-
ited by the customs of practice in the community. Miller v. Kennedy, 11 Wash. App. 272,
522 P.2d 852 (1974), afl'd per curiam, 85 Wash. 2d 151, 530 P.2d 334 (1975) (physician has a
duty to inform a patient about abnormalities in his or her body).
69. [W]e hold that parents have a right to prevent the birth of a defective child and
health care providers a duty correlative to that right. This duty requires health care
providers to impart to their patients material information as to the likelihood of fu-
ture children being born defective, to enable the potential parents to decide whether
to avoid the conception or birth of such children.
Harbeson, 98 Wash. 2d at _, 656 P.2d at 491. See also Berman, 80 N.J. at __, 404 A.2d at
14; Keogan v. Holy Family Hospital, 95 Wash. 2d 306, 622 P.2d 1246 (1980) (failure to
inform patient with angina pectoris of further tests to diagnose a heart condition consti-
tuted negligence); Gates v. Jensen, 92 Wash. 2d 246, 595 P.2d 919 (1979) (holding that the
failure to inform a patient of the availability of tests that would rule out glaucoma consti-
tuted negligence). The Gates court held that the physician's duty to inform the patient was
limited to simple, inexpensive, and relatively risk free tests. Gates, 92 Wash. 2d at -, 595
P.2d at 924. In Keogan, the court seemed to back away from these criteria: "Two of the
tests available in this case, when considering the alternative of death by heart attack were
relatively simple and risk free." Keogan, 95 Wash. 2d at _, 622 P.2d at 1255. According to
the court, the physician had a duty to inform the patient about the availability of angiogra-
phy, an invasive cardiac diagnostic procedure with a risk of 0.2 to 0.3 percent. Angiography
is only 80% effective as a diagnostic tool. Id. at __, 622 P.2d at 1249.
The risks currently associated with amniocentesis used to obtain fetal cells for READ is
less than 0.5 percent. See supra note 14. The effectiveness for detecting sickle cell anemia
and thalessemia is very high. See Kronenberg, supra note 23, at 51. Assuming that the cell
sorting technique can be adapted for use with this test, the risks would be negligible. The
costs of using READ as a routine diagnostic technique are difficult to estimate at this time.
The use of fluorescent probes would greatly reduce the cost. See Chang & Kan, supra note
26, at 32 (Chang and Kan believed that the test would soon be feasible to use in Ghana
where 140,000 tests would be required per million pregnancies).
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terial to a parent's decision to terminate or continue a pregnancy.
The tort of wrongful birth may inadvertently impose a broad duty
upon physicians to routinely screen for genetic disorders in order
to avoid liability. The costs of such defensive medicine to health
care consumers could be enormous. 0 Presumably, these costs could
be avoided since a physician could merely inform the patient of the
availability of the tests and have the patient waive the tests if she
so desires. 71 However, this approach does not truly ameliorate the
costs of defensive medicine because many, if not most, women con-
fronted with even minimal risks are likely to opt for knowledge
available through READ as long as the tests are relatively painless,
non-invasive and inexpensive. Moreover, the waiver may not be
viewed as voluntary if it was made because of the inability to pay.
In creating the doctrine of wrongful birth, courts clearly have
not anticipated the development of molecular genetics and its im-
pact on prenatal diagnosis. The result of the interaction between
the doctrine of wrongful birth and advancing molecular genetics
could be a judicially-created genetic screening program. Genetic
screening programs are not unique. In fact, most states have cre-
ated such programs for particular genetic diseases.72 The differ-
ence, however, lies in the fact that the judicially created programs
would lack safeguards necessary to prevent the disclosure of infor-
mation without consent. Patients have some statutory and legal
remedies for unauthorized disclosure, 7 but considering the stigma
70. See Keogan, 95 Wash. 2d at -, 622 P.2d at 1261. See also Griner & Glaser, Misuse
of Laboratory Tests and Diagnostic Procedures, 307 NEW ENG. J. MED. 1336 (1982). Be-
tween 1973 and 1980, St. Paul Companies, the largest medical malpractice insurer, reported
that the failure to diagnose was alleged in 25 percent of the medical malpractice suits. A
1976 HEW report revealed a similar figure. In this report, most malpractice claims in non-
surgical suits, involved inadequate testing. See Furrow, The Causes of Wrongful Life Suits:
Ruminations on the Diffusion of Medical Technologies, LAW, MED. AND HEALTH CARE, Feb.
1982, at 12. But see Capron, Tort Liability in Genetic Counseling, 79 COLUM. L. REV. 618,
666-72 (1979).
71. See Capron, supra note 70, at 671-72.
72. Seventeen states have established sickle cell anemia screening programs. Forty-two
states have screening programs for phenylketonuria. Reilly, Genetic Screening Legislation,
in ADVANCES IN HUMAN GENETICS 319, 353 (H. Harris & K. Hirschorn eds. 1975). See gener-
ally PRESIDENT'S COMMISSION, SCREENING, supra note 6, at 31-35. World-wide, over 350,000
Jewish adults have been screened for Tay-Sachs Disease. The program in the United States
has significantly decreased the number of infants born with the disease. Id. at 19-20.
73. See Riskin & Reilly, Remedies for Improper Disclosure of Genetic Data, 8 RUT.-CAM.
480 (1977). The primary sanction for improper physician disclosure of data obtained in the
professional relationship is delicensure, but only if the states provide this sanction. Some
courts have awarded damaged for disclosure of confidential medical information. Id. at 491.
Most state screening laws protect genetic data from unauthorized disclosure. See, e.g., VA.
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associated with many disorders and the type of information availa-
ble from READ, a patchwork of remedies may not be adequate to
protect patients' rights.
3. Impact of READ on a State's Ability to Affect the Abortion
Decision
During the first trimester of pregnancy, a woman's privacy inter-
est overrides any state interest in limiting abortion. 74 Similarly, the
state cannot restrict a mother's right to an abortion during the sec-
ond trimester unless the state is seeking to protect maternal
health.75 Amniocentesis is usually performed in the fifteenth or six-
teenth week of pregnancy.76 Chromosome and metabolic tests cur-
rently used for prenatal diagnosis require from three to eight
"weeks to process7 7 and occasionally need to be repeated.78 Hence,
the results of prenatal testing are unavailable until late in the sec-
ond trimester when the risks to maternal health from abortion can
be substantial.
In contrast, the results of tests using READ are available in two
weeks. 9 Since the risk to maternal health from abortion increases
with fetal age, the early availability of the results of prenatal diag-
nosis using READ should make abortion safer for the mother while
making any state interest in restricting access to abortions less
compelling. More importantly, because the Supreme Court has
held that the state cannot interfere with a mother's right to an
CODE ANN. § 32-112.23 (Cum. Supp. 1982).
74. See Roe v. Wade, 410 U.S. 113 (1973).
75. See Planned Parenthood v. Danforth, 428 U.S. 52 (1976).
76. Annas & Coyne, supra note 49, at 471.
77. Thompson & Milunsky, supra note 51, at 27.
78. Cell cultures for chromosomes and metabolic studies fail in about five to ten percent
of the cases. Id. at 29.
79. Chang & Kan, supra note 26, at 31. A new genetic diagnostic procedure has been
developed that permits prenatal testing in the first trimester. See Kazy, Rozovsky &
Bakharev, Chorion Biopsy in Early Pregnancy: A Method of Early Prenatal Diagnosis for
Inherited Disorders, 2 PRENAT. DIAGNosIs 39 (1982). In this procedure, cells of fetal origin
are removed from the chorionic villi at the site of placental implantation. These rapidly
dividing cells are then cultured for use in chromosome and metabolic tests. The culture of
these cells usually requires only two weeks. This procedure is being examined on an experi-
mental basis in this country and in Europe. See Kolata, First Trimester Prenatal Diagnosis,
221 SCL 1031 (1983). Preliminary evidence suggests that the test is safe and the cells are
identical biochemically to those obtained by amniocentesis. Id. at 1033. Interestingly, in
1982 workers using READ already recognized the potential of adapting chorionic biopsy to
diagnose hemoglobinopathies with this technique. See Orkin, Little, Kazaian & Boehm,
supra note 15, at 36.
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abortion during the second trimester except to protect maternal
health,80 the state may be powerless to restrict the decision to seek
an abortion even when the procedure is used as a means of ob-
taining preferences for certain genetic traits. Therefore, unless the
state can restrict access to the tests that provide the basis for that
preference, it will be unable to regulate use of READ to screen for
particular genetic traits.8' It may even be unconstitutional for any
state to attempt to interfere with a mother's access to information
necessary to the abortion decision. 2 Thus, any attempt to limit
prenatal diagnostic information absent a showing of a threat to
maternal health may be unconstitutional.
B. READ and Individual Rights
The fact that the READ technique can be employed to obtain a
genetic "fingerprint" from an individual to identify desirable or
undesirable genetic traits has conflicting implications. On the one
hand, the technique can be used to identify those persons particu-
larly susceptible to an undesirable trait so that steps may be taken
to protect them. On the other hand, the technique can be per-
formed upon any blood sample without the patient's consent or
knowledge. Thus, the possibility exists that information could be
obtained and used in a discriminatory manner. The use of the re-
sults of genetic testing in the work place illustrates this conflict.
The capacity of READ to detect genetically-based heightened
susceptibility to certain toxic compounds presents the opportunity
to take corrective measures to protect those individuals from expo-
sure to such toxins in the work place, either by reducing levels of
exposure or by employing hypersensitive individuals in less haz-
ardous work environments. However, this information could be
used as a basis for employment discrimination . 3 Because the
80. Danforth, 428 U.S. 52.
81. See supra notes 47-62 and accompanying text.
82. "The decision to abort, indeed, is an important, and often a stressful one, and it is
desirable and imperative that it be made with full knowledge of its nature and conse-
quences." Danforth, 428 U.S. at 52 (emphasis added).
83. See Lappe, supra note 20. At least 59 companies, including Dupont, have or may
initiate some form of screening program. Holden, supra note 20, at 336. New Jersey prohib-
its employment discrimination based upon atypical hereditary cellular or blood traits in-
cluding the sickle cell trait. Florida and North Carolina prohibit employment discrimination
based upon the sickle cell trait. See Hearings, Genetic Screening, supra note 20, at 97. West
Virginia University Law Professor Mark Rothstein testified, at these hearings, that he be-
lieved it would be beyond OSHA's statutory mandate to promulgate standards regarding the
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READ technique can be done on any blood sample, the testing
could be performed without the employees' knowledge or consent
and the information used as a basis for employment decisions.
The purported discriminatory use of information from genetic
tests in the employment context has served as the basis for several
recent discrimination suits. In Smith v. Olin,8 4 summary judgment
was granted to the defendant on a black worker's claim that he was
fired discriminatorily because he had sickle cell anemia. The Fifth
Circuit affirmed the lower court's decision without reaching the
claim, agreeing with the lower court's findings that Smith's bad
back was adequate reason for discharge from a laborer's position.
In another case,85 the Fourth Circuit has held that employment
decisions based upon the possible susceptibility of female workers
of childbearing age to toxic substances in the work place could be
raised as a business necessity defense to a disparate impact claim86
in a Title VII action. In order to assert such a defense, the court
held that the employer could show that the action was required for
employee or fetal safety and that the restrictions imposed served
use of genetic screening tests that would protect employment rights. Id. at 104. Rothstein
further stated:
[G]enetic and cytogenetic screening is a field in which the law has lagged well behind
scientific developments. There is a strong potential that new scientific discoveries
could be made in this field with a rapidity that would bring a variety of societal
problems in their wake, and with which we are not presently prepared to deal.
The danger is that these techniques will be used prematurely, indiscriminately, and
with harsh consequences for higher risk categories of workers.
Id. at 99-100. See generally Ashford, Spadafor & Caldart, Human Monitoring; Scientific
Legal and Ethical Concerns, 8 HARv. ENvT'L L. REv. 263 (1984) (containing a thorough dis-
cussion of problems and issues associated with screening in the work place).
It should be noted that the physician has an enforceable duty not to reveal confidential
information. See generally Riskin & Reilly, Remedies for Improper Disclosure of Genetic
Data, 8 RuT.-CAht. L.J. 480 (1977). The primary sanction for improper physician disclosure
of data obtained in the progessional relationship is delicensure, but only if the states pro-
vide this sanction. Id. at 491. Some courts have awarded damages for disclosure of confiden-
tial medical information. Id. Most state screening laws protect genetic data from unautho-
rized disclosure. See, e.g., VA. CoDE ANN. §§ 32.1-69 (Repl. Vol. 1979).
84. 555 F.2d 1283 (5th Cir. 1977).
85. Wright v. Olin Corp., 697 F.2d 1172 (4th Cir. 1982).
86. Employment practices that have a disproportionate adverse impact on certain groups
violate Title VII. See McDonnell Douglass v. Green, 411 U.S. 792 (1973); Griggs v. Duke
Power Co., 401 U.S. 424 (1971). As a defense to a disparate impact claim, an employer may
show that the employment practice was justified because it was necessarily related to job
performance, and thus, a business necessity. See Albemarle Paper Co. v. Moody, 422 U.S.
405 (1975); Comment, The Business Necessity Defense to Disparate-Impact Liability
Under Title VII, 46 U. CHL L. REV. 911 (1979).
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that purpose.8
A number of genetic traits have been linked to susceptibility to
pollutants and toxic substances in the work place.8 Some have a
higher incidence in specific racial groups"9 or may be gender-spe-
cific. Presumably an employer could justify an employment policy
that had a disparate racial or gender impact if he could show that
the policy was necessary and efficacious for the operation of the
business. Only three states currently have laws prohibiting employ-
ment discrimination based upon the results of sickle cell screening
tests."
Assuming that an employer can test for susceptibility to toxic
substances, it is unclear what limits the courts will place upon the
dissemination of the data. Recently, the District of Columbia Cir-
cuit Court of Appeals ruled that an employer had to turn over all
information relevant to health and safety in the work place to a
labor union, including employee medical records, as part of the
employer's duty to bargain in good faith.9 1 However, the court did
require that all names be deleted from the medical records.92 The
court held that such a limited disclosure did not violate an em-
ployee's right to medical confidentiality.93
Conceivably, genetic testing to reveal the presence of genes con-
trolling an individual's susceptibility to diseases, including can-
cer, 94 could be required as a condition to the individual's obtaining
insurance. Information about other genetic traits could also be
used to justify voluntary or compulsory sterilization and as a ba-
sis for withholding the right to obtain an education 8 or to marry.9 7
87. Wright, 697 F.2d at 1189.
88. See supra note 60.
89. See supra note 20.
90. See supra note 83.
91. Oil, Chem. & Atomic Workers Local Union No. 6418 v. NLRB, 711 F.2d 348 (D.C. Cir.
1983) (females restricted in job access as a part of a fetal vulnerability program).
92. Id. at 363.
93. Id.
94. See supra note 18; see also Cooper, Cellular Transforming Genes, 218 ScI. 80 (1982);
Marx, The Case of the Misplaced Gene, 218 ScL 983 (1982).
95. See Wexler, supra note 16, at 313. The Supreme Court has upheld a Virginia statute
permitting eugenic sterilization. Buck v. Bell, 274 U.S. 200 (1927).
96. Several states require susceptible individuals to have a blood test for sickle cell ane-
mia before entering school. See, e.g., MASS. GEN. LAWS ANN. ch. 76, § 15A (West 1982); N.Y.
EDUC. LAW § 904 (McKinney 1982).
97. A test for sickle cell anemia is required in New York for any individual who is not
Caucasian, Indian or Oriental. N.Y. Dom. REL. LAW § 14-aa(l) (McKinney 1977). However,
the results of the test are not to be used as a sole basis to deny a marriage license. Id. § 13-
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IV. THE INABILITY OF THE EXISTING REGULATORY SYSTEMS TO
DEAL WITH THE ISSUES RAISED BY READ
The complex and diverse nature of the issues raised by the
READ technique typify those issues which can be raised by other
biomedical applications of rDNA research. s In some aspects, these
issues differ from those that typically confront the regulatory pro-
cess. The problems presented by READ are not due to the inher-
ent risks of the procedure itself. Instead, the problems stem from
the myriad ethical and legal dilemmas engendered by the scientific
knowledge made available through the technique, and by the po-
tential use or abuse of that knowledge. Clearly, the regulation of
knowledge is far more perplexing than the attempt to limit the
risks involved in a substance, drug, or medical procedure, even
when an accurate assessment of the risk is difficult or impossible to
obtain. Thus, the regulatory strategies employed to protect human
safety may not necessarily be consistent with the ethical standards
of society.
A. Regulation of Diagnostic Devices Under the Food, Drug, and
Cosmetic Act
The Medical Device Amendments of 1976,99 to the Food, Drug,
and Cosmetic Act give the Food and Drug Administration (FDA)
authority to regulate medical devices, including all in vitro re-
agents used to diagnose disease in man.1°0 These amendments di-
vide all medical devices into three classes based upon the degree of
regulation required to provide reasonable assurance of the device's
safety and effectiveness. 1 1 Class I and II devices are regulated ge-
aa(2).
98. See PRESIDENT'S COMMISSION, SPLICING, supra note 4, at 51-79.
99. 21 U.S.C. §§ 360(c)-(k) (1982).
100. 21 U.S.C. § 321(h) (1982). "In vitro diagnostic products are those reagents, instru-
ments and systems intended for use in the diagnosis of disease or other conditions, including
a determination of the state of health .... Such products are intended for use in the col-
lection, separation and examination of specimens taken from the human body." 21 C.F.R. §
809.3(a) (1983).
101. 21 U.S.C. § 360c(a) (1982). A Class I device is one for which the generic controls
authorized by the Act are sufficient to assure safety and effectiveness and which is not pur-
ported or represented to be for use in "supporting or sustaining human life or for a use
which is of substantial importance in preventing impairment of human health." Id. §
360c(a)(1)(A)(i)-(ii). A Class II device is one for which normal safeguards against adultera-
tion and mislabeling are inadequate to assure safety and effectiveness, but for which suffi-
cient information exists to establish performance standards. Id. § 360c(a)(1)(B). A Class In
device is one for which there is insufficient information to determine whether controls are
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nerically and do not require premarket approval. Class III devices
require FDA approval before marketing. 102 The manufacturer of a
new device can obtain premarket approval by providing "reasona-
ble assurance" that such a device is safe and effective "under the
conditions of use prescribed, recommended or suggested" in the
proposed label.10 3
The reasonable assurance of safety standard is met by establish-
ing that "[t]he probable benefits to health from use of the device
for its intended uses and conditions of use, when accompanied by
adequate directions and warnings against unsafe use outweigh any
probable risks. '10 4 The risks in this balancing test are confined to
risks of injury or illness to the patient resulting from the use of the
diagnostic procedure. 10 5 The FDA requires the demonstration of
clinically significant results to establish that the device is
effective.106
Within the regulatory framework described above it would be
difficult for the FDA to withhold approval of a READ-utilizing test
that could be demonstrated to yield clinically significant results.
The initial application for approval of a test employing the tech-
nique would be classified as a Class III device because the test was
not delivered into commerce before May 28, 1976 and is not sub-
stantially equivalent to another device classified as Class I or IH.107
The risks to the patient associated with READ are essentially simi-
lar to those associated with amniocentesis. These risks are gener-
ally considered negligible if the procedure is performed early in the
second trimester. The benefits to health depend upon the type of
information sought by the particular test. The benefits of tests for
serious and clinically significant genetic disorders outweigh the
sufficient to provide reasonable assurance of safety and effectiveness, which cannot be classi-
fied as a Class II device and which is purported to be used in "supporting or sustaining
human life or for use which is of substantial importance to preventing impairment of human
health" or which "presents a potential unreasonable risk of illness or injury." Id. §
360(a)(1)(C) (i)-(iii).
102. Id. § 360c(a)(1)(C).
103. Id. § 360e(d)(2)(A)-(B). In addition the applicant must show good manufacturing
procedures and accurate labeling. Id. § 360e(d)(2)(C)-(D). The safety and effectiveness of
the device are to be determined "(A) with respect to the persons for whose use the device is
represented or intended (B) with respect to the conditions of use prescribed, recommended,
or suggested in the labeling ...and (C) weighing any probable benefit to health ...
against any probable risk of injury or illness from such use." Id. § 360c(a)(2)(A)-(C).
104. 21 C.F.R. § 860.7(d)(1) (1983).
105. Id.
106. Id. § 860.7(e)(1).
107. 21 U.S.C. § 360c(f)(1) (1982).
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small risks of amniocentesis. However, in the case of tests for neu-
tral genetic traits, it could be argued that there is no benefit to
health, and hence the test should be considered unsafe compared
to the minimal risks of amniocentesis.' 08
Arguably, a test for a seemingly neutral trait could have benefi-
cial value to some groups of individuals. Moreover, given the mini-
mal risks of the diagnostic procedure, an FDA decision not to ap-
prove the test could be construed as interfering with a patient's
right to medical autonomy and/or her constitutional right to be
free from restraints in obtaining an abortion.
In deciding whether to approve a diagnostic device the Medical
Device Amendments clearly do not permit the FDA to consider
concerns relating to the misuse, unauthorized use or impact of a
technique on medical practice and society.109 The Act, however,
does allow the sale, distribution or use of an approved device to be
restricted.110 For example, the FDA has used section 360j(e)(1)1"
to propose restrictions on the use of an in vitro test for detecting
neural tube defects by screening for the presence of alpha-
fetoprotein in maternal blood. The test lacks specificity unless co-
ordinated with other diagnostic tools and confirmed through amni-
ocentesis. The FDA based its proposed restrictions on the likeli-
hood that the test's inherent lack of specificity would give parents
false warnings as to the possibility that their child could have a
neural tube defect. The FDA reasoned that the alerted parents
would opt for unnecessary abortions rather than utilize the follow-
up tests necessary to confirm the initial diagnosis." 2 All of the un-
108. See supra note 14.
109. See generally 21 U.S.C. § 360j(e)(1) (1982).
110. The Secretary may by regulation require that a device be restricted to sale, distribu-
tion, or use-(A) Only upon the written or oral authorization of a practitioner li-
censed by law to administer or use such device, or (B) Upon such other conditions as
the Secretary may prescribe in such regulation; if, because of its potentiality for
harmful effect or the collateral measures necessary to its use, the Secretary deter-
mines that there cannot otherwise be reasonable assurance of its safety and
effectiveness.
Id.
111. Id.
112. 45 Fed. Reg. 74,158-60 (1980). In the United States between 0.1 and 0.2 percent of
all live births have neural tube defects (e.g., spina bifida). A fetal protein, related to the
fetal immunological system, alpha-fetoprotein (AFP), is an indicator of the presence of a
neural tube defect. AFP will appear at elevated levels in the maternal blood in about 50 of
1,000 mothers at 14 weeks of pregnancy. However, only one out of 1,000 of the mothers will
be carrying a fetus with a neural tube defect. Following a second blood test about 30 of
these mothers still showing an elevated level of AFP will have to undergo sonograms to
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desirable effects used to justify the restriction related directly to
the effectiveness of the test.113 Despite these concerns, the FDA
ultimately decided to approve the test without restriction." 4
Since, in most instances, tests using READ will be considered
both safe and effective, section 360j(e) restrictions probably will
not be placed on the tests. Thus, it appears that the existing FDA
regulatory mechanisms will not permit the agency to consider all of
the possible problems surrounding this technique.
B. Regulation of Genetic Screening Under the Occupational
Safety and Health Act
Congress enacted the Occupational Safety and Health Act (OSH
Act)1 5 "to assure as far as possible every working man and woman
in the Nation safe and healthful working conditions . ".".., The
OSH Act imposes a "general duty" on every employer to furnish
each employee with a work place "free from recognized
hazards." 1 7 Furthermore, with regard to toxic materials or harmful
physical agents, the Occupational Safety and Health Administra-
tion (OSHA) must set standards which assure "[t]o the extent fea-
sible, on the basis of the best available evidence that no employee
will suffer material impairment of health or functional capacity
even if such employee has regular exposure to the hazard dealt
with by such standard for the period of his working life.""18 Any
eliminate false positive results caused by twins and improper estimation of fetal age. This
usually reduces the number of at risk mothers to 15 per 1,000. Amniocentesis is usually
performed at 22 weeks of gestation to measure AFP in the amniotic fluid. Of ten mothers
with elevated AFP in the amniotic fluid only one will be carrying a normal child. Id. at
74,158-59.
113. The proposed restrictions addressed the concerns of some critics of the test that its
general use will overburden the allocation of the limited medical resource of amniocentesis.
Id. at 74,161 (1980). See generally PRESIDENT'S COMMISSION, SCREENING, supra note 6. The
FDA however did not include this concern among its justifications for restricting the test
under 21 U.S.C. § 360j(e). 45 Fed. Reg. 74,159 (1980).
114. 48 Fed. Reg. 27,780 (1983); see Sun, FDA Draws Criticism on Prenatal Test, 221 SCL
440 (1983).
115. 29 U.S.C. §§ 651-678 (1982).
116. Id. § 651.
117. Section 654, entitled "Duties of employers and employees," reads in part:
(a) Each employer-
(1) Shall furnish to each of his employees employment and a place of employ-
ment which are free from recognized hazards that are causing or are likely to cause
death or serious physical harm to his employees ....
21 U.S.C. § 654(a)(1) (1982).
118. Id. § 655(b)(5) (emphasis added). The term "occupational safety and health stan-
dard" is defined as: "[A] standard which requires conditions, or the adoption of one or more
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standard must prescribe the use of "appropriate forms of warning"
to ensure that employees are "apprised of all hazards" to which
they are exposed.11 9 The standard may prescribe the type of medi-
cal examinations or other tests which the employer must make
available to employees exposed to hazardous materials.120
READ, which can accurately diagnose susceptibility to "toxic
materials or physical agents,"'-' may constitute a method of assur-
ing a safe or healthful work environment. Certainly, it could be
argued that the technique is a means of ensuring that no employee
suffers material health impairment from exposure to such hazard-
ous materials.
Assuming that the use of the READ technique, or one like it,
were required in an OSHA standard,122 the OSH Act does not pro-
tect employees from dismissal if they are more susceptible to a
hazardous material present in the work place. In fact, the District
of Columbia Circuit Court of Appeals recently held that the "gen-
eral duty"'123 clause in the OSH Act does not protect employees
from dismissal based upon susceptibility to hazardous materials. 24
practices, means, methods, operations, or processes, reasonably necessary and appropriate to
provide safe or healthful employment or places of employment." Id. § 652.
119. Id. § 655(b)(7).
120. Id.
121. Woo, Alpha-1 Antitrypsin Deficiency and Pulmonary Emphysema: Identification of
Recessive Homozygote by Direct Analysis of the Mutation Site in the Chromosomal Genes,
Cold Spring Harbor Symposium on the Application of Recombinant DNA to Human Dis-
ease (1982). See supra note 20.
122. Dr. Bernard Goldstein of the Environmental Protection Agency has predicted that
within five to ten years rDNA techniques (presumably the READ technique) will be em-
ployed to detect health effects in individuals exposed to toxic substances. See 15 ENV'T REP.
(BNA) 1059 (1984).
123. See supra note 117 and accompanying text.
124. American Cyanamid Co. v. Oil Chem. and Atomic Workers Int'l Union, 9 O.S.H. REP.
(BNA) 1596 (1982), aff'd, 11 O.S.H. REP. 2193 (D.C. 1984). Thirteen women were required to
submit to sterilization in order to keep their jobs working in an area with high levels of lead
which might cause birth defects. Five women submitted to sterilization, but all thirteen lost
their jobs. The commission granted American Cyanamid's motion for summary judgment in
suit alleging discriminatory employment policies. The dissent of Commissioner B. Cottine
stated that the general duty clause in the Occupational Safety and Health Act, 29 U.S.C. §
654(a)(2), could be used to prevent this type "of employment policy. American Cyanamid, 9
O.S.H. REP. at 1601 (Cottine, Comm'r, dissenting). See also Hearings, Genetic Screening,
supra note 20.
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C. Regulation of READ Under the Toxic Substances Control Act
The Toxic Substances Control Act (TSCA)12 5 regulates some ap-
plications of rDNA research employed in biotechnology.126 Under
section 5 of TSCA, the manufacturer of a new "chemical sub-
stance" must notify the Environmental Protection Agency (EPA)
of its intention to manufacture or process such a substance. 27 This
section appears to require the manufacturer of DNA probes and
restriction enzymes used in the READ technique to notify the
EPA before beginning manufacture. 2 " However, the TSCA specifi-
cally excludes from the definition of the term "chemical sub-
stance": "any food, food additive, drug, cosmetic, or device (as
such terms are defined in section 201 of the Federal Food, Drug,
and Cosmetic Act) when manufactured, processed or distributed in
commerce for use as a food, food additive, drug, cosmetic or de-
vise. 1 29 In vitro reagents are included in the definition of a "de-
vice" under 29 U.S.C. section 321(h) of the Food, Drug and Cos-
metic Act. °30 Thus, it would appear that the TSCA prevents the
EPA from considering the issues associated with READ. If the
concerns surrounding the use of this technique merit regulatory at-
tention, new mechanisms will have to be designed to specifically
deal with the special complexity produced by this technology.
V. CONCLUSION
The issues associated with READ illustrate the complications
that may be encountered as rDNA research generates new bi-
omedical techniques that may be applied to treat and alter human
genes. The inability of existing regulatory strategies to address
these issues suggests that further inadequacies may be encountered
125. 15 U.S.C. §§ 2601-2629 (Supp. 1981).
126. It has been suggested that some of the industrial applications of biotechnology could
be regulated under the Toxic Substances Control Act. McGarity & Bayer, Federal Regula-
tion of Emerging Genetic Technologies, 31 VAND. L. REv. 461, 505-06 (1983) (the legal au-
thority to regulate genetically engineered microorganisms would turn upon the agency's
ability to establish that a microorganism is a "chemical substance" under § 2602).
127. 15 U.S.C. § 2604(a) (Supp. 1981). The term "chemical substance" is defined as:
"[A]ny organic or inorganic substance of a particular molecular identity including-(i) any
combination of such substances occurring in whole or in part as a result of a chemical reac-
tion or occurring in nature . . . ." Id. § 2602(2)(A).
128. The term "manufacture" is defined to mean "to import ... produce, or manufac-
ture." Id. § 2602(7).
129. Id. § 2602(2)(B)(vi).
130. 29 U.S.C. § 321(h) (Supp. 1981).
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in regulating other biomedical applications of rDNA technology.
READ does not directly endanger human health, however, it does
have the potential for misuse and the invasion of an individual's
privacy interests. In this respect, the lack of any effective in-place
mechanism to ensure consideration of these problems is
troublesome.
Clearly, as new biomedical applications of rDNA develop, careful
consideration will have to be given to the effectiveness of existing
regulatory strategies. However, because of the rapidity with which
advancements can and are being made in the field of rDNA re-
search, prospective examination of potential problems is needed to
ensure that society is willing and able to accept the benefits and
burdens of this research.

